Closed opportunity The company closed in late 2024, indicating a potential need for asset or patient recruitment partnerships to monetize remaining IP, legacy data sets, or transition services for clients who previously engaged with Aspen Clinical Research.

Clinical capacity gap With a 20,000 sq.ft. facility and 18 bed in-patient capacity, Explore partnerships to reconstitute or repurpose the site for Phase II–IV clinical pharmacology trials, device studies, or hybrid trials in collaboration with local hospitals and CRO networks.

Therapeutic scope Aspen offered multi-therapeutic trial support across all phases and devices; sales opportunities exist in providing scalable site management, data collection, and regulatory support to CROs and sponsor clients seeking consolidated site services.

Regional focus Based in Orem, Utah, there is potential to target regional biopharma and medtech firms seeking Utah-based trial sites or to complement to-scale national CRO networks with a mid-market, flexible site option.

Financial footprint Reported revenue of 25–50 million suggests a mid-size clinical research footprint; identify opportunities to offer co-management, transition services, or continuity arrangements for existing client programs and archived data assets.